Companies/Collegium Pharmaceutical, Inc.

Company profile

Collegium Pharmaceutical, Inc.

NASDAQ: COLL · Healthcare · Drug Manufacturers - Specialty & Generic

PublicHQ Stoughton, MACIK 0001267565Reports USD

#176 of 1,402 Healthcare companies by revenuetop-decile growth

EA Score

73B

FH 81DQ 64GM 68SS 71

v0.1 · 65/100 weight · provisional

↑ Piotroski F, operating margin · ↓ growth stability, balance-sheet leverage

Methodology →

Revenue TTM

$796.3M

Rev growth YoY (TTM)

+19.9%

Net income (FY)

$62.9M

Employees

357

Market cap

$1.2B

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$780.6M$780.6M2025

Net income$62.9M$62.9M2025

Operating income$179.6M$179.6M2025

Total assets$1.7B$1.7B2025

Liabilities$1.4B$1.4B2025

Equity$301.7M$301.7M2025

Revenue trend

FY2024 – FY2025 · USD

$144.9M

FY24

$145.3M

FY24

$159.3M

FY24

$631.4M

FY24

$177.8M

FY25

$188.0M

FY25

$209.4M

FY25

$780.6M

FY25

Revenue by segment

Filed disclosures · FY2025

By product

Belbuca36%

Xtampza ER32%

Nucynta IR19%

Nucynta ER13%

By geography

Not disclosed.

The read

Collegium Pharmaceutical, Inc. booked $780.6M in FY2025 revenue, growing 273% year over year — faster than 91% of Healthcare companies we track, at a 8.1% net margin.

Peers · Healthcare

ORIC Pharmaceuticals, Inc.——PROCEPT BioRobotics Corporation63C Lumexa Imaging Holdings, Inc. Common Stock——Personalis, Inc.58C

Key facts

CEOVikram Karnani

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersStoughton, MA

ExchangeNASDAQ: COLL

Employees357

IPO date2015-05-07

Latest filings

8-K2026-05-15 8-K2026-05-12 10-Q2026-05-07 8-K2026-05-07 DEF 14A2026-04-07 8-K2026-04-07 8-K2026-03-19 10-K2026-02-26

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.